Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CTx-2103 (Buspirone Hydrochloride) is a novel, trimodal, extended-release tablet of buspirone incorporating Cingulate’s proprietary PTR™ drug delivery platform, and is being studied for the treatment of anxiety and/or anxiety-related disorders.
Lead Product(s): Buspirone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-2103
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Cingulate Therapeutics, LLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022